AbbVie has achieved top-line results in a fourth pivotal Phase III clinical trial evaluating risankizumab for the treatment of psoriasis.
Results from the first of a two-phase study showed that after 16 weeks of treatment, risankizumab met the co-primary endpoints of at least a 90% improvement in the Psoriasis and Severity Index versus placebo.
The primary endpoint was also met in the second phase of the study, which evaluated the safety of continuous therapy with risankizumab versus randomised withdrawal.
Risankizumab is not approved by regulatory authorities and its safety and efficacy have not been established.
Risankizumab is part of a collaboration with Boehringer Ingelheim, with AbbVie leading future development and commercialisation globally.